Healthcare | November 21, 2024
Emcure and MS Dhoni drive India’s fight against Anemia
Emcure has launched an awareness campaign to help spread the word about male anemia
Emcure has launched an awareness campaign to help spread the word about male anemia
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Inclacumab was generally well tolerated in THRIVE-131
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Subscribe To Our Newsletter & Stay Updated
